Provectus Biopharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Provectus Biopharmaceuticals generated cash of -$2,571,978, which is more than the previous year. Cash used in financing activities reached the amount of $2,191,555 last year. Net change in cash is therefore -$404,908.
Cash Flow
| 2014 | -13.84M | -70.59K | 15.61M |
|---|---|---|---|
| 2015 | -17.41M | -6.13K | 14.20M |
| 2016 | -21.93M | 0 | 8.92M |
| 2017 | -10.34M | -30.4K | 9.31M |
| 2018 | -5.20M | 0 | 5.15M |
| 2019 | -6.19M | 0 | 6.75M |
| 2020 | -4.08M | 0 | 3.60M |
| 2021 | -1.01M | 0 | 4.02M |
| 2022 | -3.04M | 0 | 1.36M |
| 2023 | -2.57M | 0 | 2.19M |
PVCT Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 1.43M | 3.10M | 97.23K | 590.70K | 50.98K | 105.50K | 1.16M | 14.17M | 17.39M | 15.69M |
Operating activities | ||||||||||
Net income | -3.10M | -3.55M | -5.53M | -6.67M | -6.92M | -8.15M | -13.51M | -24.42M | -24.50M | -10.24M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 8.92K | 10.89K | 12.86K | 241.79K | 685.21K | 685.21K | 686.98K | 684.23K | 684.28K | 679.65K |
Stock-based compensation expense | 2.85K | 3.02K | 23.68K | 134.75K | 22.97K | 0 | 0 | 20.16K | 670.57K | 533.89K |
| Deferred income tax benefit | 2.85K | 3.02K | 23.68K | 134.75K | 22.97K | 0 | 0 | 20.16K | 670.57K | 533.89K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 4.48K | -1.44K | 50.32K | 4.90K | 528.23K | 216.82K | 517.56K | 1.59M | 0 |
Inventories | 0 | -4.48K | 1.44K | -50.32K | -4.90K | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -418.37K | 807.07K | 331.14K | -170.41K | -2.18M | 41.54K | 1.79M | 32.69K | 1.44M | 91.83K |
Cash generated by operating activities | -2.57M | -3.04M | -1.01M | -4.08M | -6.19M | -5.20M | -10.34M | -21.93M | -17.41M | -13.84M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -2 | 0 | 0 | 0 | 0 | 0 | -30.4K | 0 | -6.13K | -70.59K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 0 | 0 | 0 | 0 | 0 | -30.4K | 0 | -6.13K | -70.59K |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 962.22K | 418.67K | 268.94K | 80K | 1.59K | 3.63M | 13.65M | 11.12M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 2.19M | 0 | -248.17K | -105.98K | 6.48M | -4.47M | 9.30M | 0 | 0 | 0 |
Cash used in financing activities | 2.19M | 1.36M | 4.02M | 3.60M | 6.75M | 5.15M | 9.31M | 8.92M | 14.20M | 15.61M |
Net Change In Cash | -404.90K | -1.67M | 3.00M | -493.47K | 539.72K | -54.51K | -1.06M | -13.01M | -3.21M | 1.69M |
Cash at end of period | 1.02M | 1.43M | 3.10M | 97.23K | 590.70K | 50.98K | 105.50K | 1.16M | 14.17M | 17.39M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |